DaRT alpha radiation for recurrent glioblastoma
Part of Cancer clinical trials.
This trial tests a device called DaRT that delivers alpha radiation directly to a recurrent glioblastoma tumor. It may help patients who cannot have surgery and have a single, small tumor regrowth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 85 years old.
- You have a confirmed diagnosis of glioblastoma (grade 4 brain tumor) that has come back after treatment.
- Your recurrent tumor is a single spot, no larger than 3 cm, seen on an MRI with contrast.
- You cannot have surgery to remove the tumor because of medical reasons, personal choice, or risky location.
- You had standard radiation and temozolomide chemotherapy at least 4 months ago.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy (retifanlimab), a targeted drug (bevacizumab), and low-dose radiation for people whose glioblastoma has come back. The goal is to see if this treatment can help shrink or slow the tumor.
This trial tests a combination of MRI-guided laser surgery, a wearable device (Optune) that sends electric fields to the brain, and an immunotherapy drug (pembrolizumab/Keytruda) for people whose glioblastoma has come back. The goal is to see if this approach is safe and works better than standard treatments.
This trial tests a new, shorter course of radiation therapy (called hypofractionation) for people with glioblastoma that has come back. It is for patients who have already had radiation and are doing well enough to consider another round.
This trial tests a special radiation device (DaRT) placed directly into skin cancer tumors. It is designed for patients with weakened immune systems (immunocompromised) who have a single skin cancer lesion on the skin (not spread elsewhere).
This trial tests a targeted radiation device (DaRT seeds) to treat certain cancers on the skin, in the mouth, or in superficial soft tissue. It may help when standard treatment (like surgery or regular radiation/chemo) hasn’t worked, isn’t safe, or isn’t wanted.
This trial tests a new radiation treatment that targets tumor cells directly. It may help people with a specific type of aggressive brain tumor that has grown after standard treatments.
Hear when a new Recurrent Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.